WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Case Study: Hepatitis B Management and Herbal Medicine Intervention in a Long-term Patient

Dr. Dr. Godwin Ayittey (FMERU)

Doc., Ph.D., MBA, MSc, BSc, Cert A
Todah Hospital- Obuasi
Email: ayitteygodwinexcel@yahoo.com

ABSTRACT:

Hepatitis B is a significant global health challenge, particularly in regions with limited access to advanced medical care. This case study explores the experience of a 35-year-old nurse who has battled chronic Hepatitis B for a decade. Despite prolonged treatment with conventional antiviral agents like lamivudine and tenofovir, the virus persisted in her bloodstream, and her liver function continued to deteriorate. The study investigates the effectiveness of herbal medicine, specifically Todah Heb-Go, in managing her condition. The research adopts a mixed-method approach, incorporating quantitative data from clinical tests and qualitative insights from interviews and observations. The results reveal a significant reduction in viral load and an improvement in liver function following the introduction of Todah Heb-Go, suggesting that the herbal treatment offers a viable alternative for patients who do not respond to conventional therapies. Additionally, the study highlights the social stigma and psychological challenges associated with chronic Hepatitis B, particularly regarding marriage prospects. Ethical considerations, including informed consent and confidentiality, were prioritized throughout the research. While the findings are promising, the study's limitations, including its focus on a single subject, underscore the need for further research to validate the efficacy and safety of Todah Heb-Go in broader populations.

Keywords: Hepatitis B and herbal treatment

1. INTRODUCTION

Introduction

Hepatitis B, a viral infection upsetting the liver, remains a significant global health alarm, predominantly in areas with restricted access to advanced health care. The virus can lead to chronic liver conditions, including cirrhosis and hepatocellular carcinoma. Gifty, a 35-year-old nurse, has been fighting Hepatitis B for the past decade. Confronted with the societal humiliation and the possible consequences for her personal life, as well as her wish for marriage, Gifty turned to herbal medicine as an alternative treatment approach. The management of chronic Hepatitis B infection often involves the use of antiviral agents such as lamivudine and tenofovir, which have been widely recognized for their efficacy in reducing viral replication. In this case, the patient was administered a combination of lamivudine and tenofovir for one year. Despite this treatment, the virus persisted in the bloodstream, and the patient continued to exhibit clinical signs and symptoms associated with Hepatitis B.

Problem Statement

Despite prolonged treatment with Lamivudine, Gifty's Hepatitis B infection persisted, leading to deteriorating liver function and social challenges. This case highlights current antiviral therapies' limitations and alternative medicine's potential role in managing chronic Hepatitis B, especially when conventional treatments fail to yield the desired results.

Objectives

1. To assess the efficiency of herbal medicine in tumbling the viral load and refining liver function in patients with chronic Hepatitis B who have not responded to orthodox antiviral treatment.
2. To explore the social and psychological impacts of chronic Hepatitis B on patients, predominantly in the framework of marriage and societal discernments.

Questions

1. What are the observed effects of herbal medicine on the viral load and liver function in Gifty Quaye's case?
2. How does the social stigma associated with Hepatitis B affect the personal lives and mental well-being of patients?

Ethical and Cultural Considerations

Confidentiality: Ensuring Gifty's medical condition remains confidential, particularly given her concerns about social stigma and marriage prospects.

Informed Decision: Gifty made an informed choice to try herbal medicine, understood the risks and benefits, and maintained regular follow-ups with her healthcare provider to monitor her condition.

Limitations

Sample Size: The study concentrations were on a single subject, limiting the findings' generalizability.

2. LITERATURE REVIEW

Hepatitis B and Antiviral Treatment

Hepatitis B is a main global fitness issue, with persistent instances main to extreme liver headaches. Antiviral remedies, which includes Lamivudine, goal to suppress viral replication and save you from liver damage. however, resistance to Lamivudine and different antiviral pills can increase, mainly to remedy failure (Lok & McMahon, 2009). Studies have shown that long-term use of Lamivudine can result in viral resistance mutations, necessitating opportunity therapeutic techniques (Yuen et al., 2001).

Limitations of Conventional Antiviral Therapy

The development of drug resistance and suboptimal response in a few sufferers underlines the restrictions of cutting-edge antiviral remedies. Studies suggest that a large share of sufferers won't achieve sustained virological suppression with Lamivudine, main to persistent viral replication and liver harm (Chang et al., 2004). This necessitates exploring different remedy options, which include alternative medicinal drugs.

Herbal Medicine in Hepatitis B Treatment

Herbal medicine has been used historically in many cultures for the treatment of liver diseases, such as Hepatitis B. A few natural formulations have proven promise in medical trials for antiviral and hepatoprotective homes (Liu et al., 2003). For instance, studies on traditional Chinese medication have indicated potential advantages in lowering viral load and enhancing liver function (Wang et al., 2002).

Social and Psychological Impact of Hepatitis B

The social stigma associated with Hepatitis B can significantly affect the intellectual health and pleasantness of the existence of sufferers. Worrying about discrimination and social exclusion can lead to psychological misery and reluctance to disclose their situation, impacting personal relationships and marriage possibilities (Lee et al., 2015). Information on those social dynamics is crucial for providing holistic care to patients.

3. RESEARCH METHODOLOGY

Introduction

This subdivision frameworks the research methodology employed to assess the efficiency of herbal medicine in dealing with chronic Hepatitis B and to discover the social and psychological influences of the disease on patients. The study employs a combined-method approach, merging quantitative and qualitative data gathering and scrutiny procedures to accomplish wide-ranging understandings.

Research Design

The research implements a case study strategy concentrating on Gifty, a 35-year-old nurse with chronic Hepatitis B. This design permits a detailed exploration of her experiences and responses to alternative treatment.

Participants

Since the study centers around a single case, Gifty is the primary participant.

Data Collection Methods

Quantitative Data

Medical Records Review: Examination of Gifty’s medical records, including liver function tests (LFTs), viral load measurements, and other relevant clinical data before and during the use of herbal medicine.

Herbal Medicine Regimen Documentation: Detailed documentation of the specific herbal treatments used, including dosage, frequency, and duration.

Health Assessment: Gifty underwent a health assessment at the start and end of the study to measure changes in viral load, eye color, palm color, and overall health.

Symptom Tracking: A symptom severity scale (0-5) was used to quantify the intensity of jaundice, joint pains, dark urine, abdominal pains, fatigue, and loss of appetite

Qualitative Data

Interviews

Conduct semi-structured interviews with Gifty at regular intervals to gather personal insights on her experiences with Todah Heb-Go, any noticeable changes in her symptoms, and the social stigma she faces. Use an interview guide with open-ended questions to facilitate in-depth discussions.

Observation Observations

Observe Gifty's overall well-being and document any changes in physical appearance, behavior, and mental state. Record observations in a structured format to identify trends and patterns over

Data Collection Instruments

Interview Guide: The researcher Developed an interview guide with open-ended questions to facilitate in-depth discussions during interviews and focus groups.

Medical Data Collection Form: The investigator Created a form to systematically record and track clinical data from medical records.

Data Analysis

Quantitative Data Analysis

Descriptive Statistics: Use descriptive statistics to summarize Gifty's clinical data, such as changes in viral load and liver function test results over time.

Comparative Analysis: Compare clinical data before and after the introduction of herbal medicine to assess any changes in her condition.

Qualitative Data Analysis

Thematic Analysis: Conduct thematic analysis of interviews and observations to identify common themes related to the effectiveness of herbal medicine, social stigma, and psychological impacts.

Reporting and Review

Prepare interim reports summarizing Gifty's progress at regular intervals (monthly).

Share these reports with Gifty for review and feedback. Compile a comprehensive final report detailing the entire treatment process, clinical outcomes, and qualitative insights. Present the findings to relevant stakeholders, including healthcare providers and researchers, to contribute to the broader understanding of alternative treatments for chronic Hepatitis B.

Ethical Considerations

Informed Consent: Obtain informed consent from Gifty and all other participants involved in interviews and observations.

Confidentiality: Ensure confidentiality by anonymizing personal data and securely storing all collected information.

Cultural Sensitivity: Respect cultural beliefs and practices related to alternative medicine and address any cultural concerns raised by participants.

Limitations

Generalizability: The study's findings are based on a single case, limiting the generalizability to the broader population.

Subjectivity: Qualitative data is subject to the personal biases and perceptions of the participants.

Herbal Medicine Variability: The effectiveness of herbal treatments varies based on the specific formulations used, limiting the findings' reproducibility.

This research methodology chapter details the approach taken to investigate the potential benefits of herbal medicine for a chronic Hepatitis B patient and the social and psychological challenges faced. Using quantitative and qualitative methods, the study aims to provide a holistic understanding of the impact of alternative treatments and the social dynamics associated with chronic Hepatitis B.

4. PROCEDURE

IMPLEMENTATION OF THE HERBAL MEDICATION (TODAH HEB-GO)

Initial Consultation and Assessment

Gifty's complete medical history was reviewed, including past, and current treatments, liver function tests (LFTs), and viral load measurements. Any allergies, pre-existing conditions, and current medications were documented.

Physical Examination

A thorough physical examination focused on signs of liver dysfunction (e.g., jaundice, ascites, hepatomegaly). Note the eye color, skin color, and palm color as part of baseline observations.

Baseline Laboratory Tests

Order Baseline laboratory tests including LFTs, viral load measurements, and other relevant clinical tests were ordered. The researcher ensured these tests were conducted and the results were documented before starting the herbal regimen.

Informed Consent

The purpose, potential benefits, and risks of Todah Heb-Go herbal medicine were explained to Gifty. The investigator obtained written informed consent from Gifty, ensuring she understood and agreed to the treatment plan.

Educational Session

Detailed information about the herbal medicine, including expected outcomes and possible side effects was provided. The importance of adherence to the treatment regimen and regular follow-ups was discussed.

Preparation and Administration of Todah Heb-Go

Herbal Medicine Preparation

Ensured Todah Heb-Go was prepared according to traditional or standardized methods, maintaining consistency in dosage and formulation.

Dosage and Administration

The appropriate dosage based on Gifty's weight, age, and severity of her condition were determined. The first dose was administered under supervision to monitor for any immediate adverse reactions. Both written and verbal instructions were provided for Gifty to follow at home, including the exact dosage, frequency, and method of administration.

Monitoring and Follow-Up

Regular Monitoring:

Schedule regular follow-up visits to monitor Gifty's progress. At a clinical visit, physical examinations were conducted on her, examining her eye color changes, skin color, palm color, abdominal pains, etc.

Collect blood samples for LFTs and viral load measurements at specified intervals (e.g., monthly).

Adverse Effects Monitoring:

Gifty was instructed to report any side effects or unusual symptoms immediately.

A log of any reported side effects and adjustments to the treatment regimen were maintained.

Data Collection and Documentation

Medical Records Review:

Continuously reviewed and updated Gifty's medical records with new laboratory results, clinical observations, and treatment progress. Ensured accurate documentation of any changes in her condition, both positive and negative.

Herbal Medicine Regimen Documentation

Detailed records of the herbal medicine used, including batch numbers, preparation dates, and any variations in formulation were kept. The dosage, frequency, and duration of herbal treatment for each follow-up period were documented.

5. RESULTS, DISCUSSION, CONCLUSION, AND RECOMMENDATIONS

RESULTS

Table 1: The table below shows the Hepatitis B test conducted before the herbal medication administration.

DATE	TEST	RESULT	VIRAL LOAD	MEDICATION
12/01/21	**HBeAg**	**Positive**	**1944 or 334IU/ml**	**Lamivudine**
12/06/21	**HBeAg**	**Positive**	**2944 or 506IU/ml**	**Tenofovir Disoproxil Fumarate (TDF)**

30/11/21	**HBeAg**	**Positive**	**2945 or 506IU/ml**	**Tenofovir Alafenamide (TAF)**
01/02/22	**HBeAg**	**Positive**	**2945 or 506IU/ml**	**Tenofovir Alafenamide (TAF)**

Across all the dates listed, the Hepatitis B Antigen (HBeAg) test was constantly positive. HBeAg was an indicator of active viral replication, and its positivity indicated that the virus was aggressively replicating in the patient's body.

The viral load remains constant at 2944 or 506IU/ml across all the test dates. This indicates no substantial transformation in the amount of Hepatitis B virus (HBV) DNA in the blood, despite the different medications being administered.

The patient was treated with three different antiviral medications during this period: Lamivudine (12/01/21), Tenofovir Disoproxil Fumarate (TDF) (12/06/21), and Tenofovir Alafenamide (TAF) (30/11/21 and 01/02/22) Despite changing medications, the patient's HBeAg status remained positive, and the viral load showed no reduction.

Table 2: The table below shows the Hepatitis B test conducted before, during, and after the herbal medication

Medication.

DATE	TEST	RESULT	VIRAL LOAD	MEDICATION
01/03/22	HBeAg	Positive	2944 or 506IU/ml	Todah Heb-Go
02/06/22	HBeAg	Target not Detected	302 or 52IU/ml	Todah Heb-Go
30/11/22	HBeAg	Target not Detected	110 or 19IU/ml	Todah Heb-Go
01/02/23	HBeAg	Target not Detected	54 or 10IU/ml	Todah Heb-Go
12/06/23	HBeAg	Target not Detected	10 or 1U/ml	Todah Heb-Go

Initial Test (01/03/22): The initial test shows a positive HBeAg result, indicating active viral replication and a higher level of contagion. The viral load (2944 or 506IU/ml) was quite high, confirming the existence of a substantial quantity of the Hepatitis B virus in the blood.

Second Test (02/06/22): By the second test, the HBeAg was "Target not Detected," meaning the antigen was no longer detectable, suggesting a reduction in viral replication. The viral load (302 or 52 IU/ml) had also significantly decreased, indicating that the medication (Todah Heb-Go) effectively lowered the virus levels in the blood.

Third Test (30/11/22): In this test, the HBeAg remained undetectable, and the viral load continued to decrease, suggesting ongoing virus suppression. The patient's condition appeared to be improved, with the virus being less active.

Fourth Test (01/02/23): The test showed that the HBeAg remained undetectable, and the viral load dropped even further. This suggested the medication effectively controlled the virus and reduced its replication to a lower level.

Fifth Test (12/06/23): The final test showed that the HBeAg remained undetectable, and the viral load dropped even further. This suggested the medication effectively controlled the virus and reduced its replication to a low level.

DISCUSSION

The data in Table 1 suggests that the patient did not respond effectively to the antiviral treatments in reducing viral replication using Tenofovir and Lamivudine as evidenced by the persistent HBeAg positivity and stable viral load. The lack of response indicates resistance to the antiviral medications, or that the chosen medications were insufficient to lower the viral load in this patient.

The data further suggests in Table 2 a positive trend in the patient's condition, with the HBeAg shifting from a positive to undetectable status, indicating a reduction in viral replication. The viral load has decreased progressively over the treatment period. It further suggested that "Todah Heb-Go" contributed to the control of the Hepatitis B virus. The consistent reduction in viral load and the absence of detectable HBeAg support the idea that the treatment worked effectively over time.

The interviews and observations with or on the patient provided compelling evidence of significant improvement in the patient's condition. Notably, the absence of key symptoms such as abdominal pain, jaundice, and other liver-related issues indicates a positive response to treatment or the natural resolution of the underlying health problem. The disappearance of abdominal pain, a common symptom associated with gastrointestinal or hepatic issues, suggests that the inflammatory or obstructive processes have been effectively managed or resolved. Furthermore, the resolution of jaundice, typically a sign of liver dysfunction, implies that liver function has either normalized or improved considerably. This is indicative of successful medical intervention. The fact that other related symptoms are no longer present further supports the conclusion that the patient's health has significantly improved.

These findings underscore the importance of continuous monitoring and thorough assessments in managing patients with liver-related conditions. The absence of symptoms not only indicates an improvement in the patient's clinical status but also highlights the potential effectiveness of the treatment regimen. Further follow-up will be necessary to ensure sustained recovery and to monitor for any possible recurrence of symptoms.

The management of chronic Hepatitis B infection often involves antiviral agents such as lamivudine and tenofovir, which have been widely recognized for their efficacy in reducing viral replication. In this case, the patient was administered a combination of lamivudine and tenofovir for one year. Despite this treatment, the virus persisted in the bloodstream, and the patient continued to exhibit clinical signs and symptoms associated with Hepatitis B. This persistence suggests potential issues such as viral resistance, suboptimal drug efficacy, or other patient-specific factors have influenced the treatment outcome.

Interestingly, the introduction of Todah Heb-Go, an alternative or adjunctive therapy, resulted in a significant reduction in the viral load, as confirmed by viral load tests. The drastic reduction observed indicates that Todah Heb-Go has a potent antiviral effect against the Hepatitis B virus, which was not fully achieved by the conventional therapy of lamivudine and tenofovir alone. This finding suggests that Todah Heb-Go either enhances the effectiveness of the existing treatment regimen or directly inhibits the virus through a different mechanism of action.

The observed results raise important questions regarding the potential role of Todah Heb-Go in treating chronic Hepatitis B, particularly in cases where standard antiviral therapy proves inadequate. Further research is warranted to explore the pharmacodynamics, safety, and long-term efficacy of Todah Heb-Go in managing Hepatitis B. Additionally, studies investigating the synergistic effects of Todah Heb-Go with other antiviral agents could provide valuable insights into optimizing treatment protocols for patients with chronic Hepatitis B infection.

Hepatitis B significantly delayed Gifty's marriage, as she was anxious about her medical condition being discovered by her Pastor, who would likely require such a test. Additionally, she feared that she might be operated and her inability to breastfeed her baby might attract public attention.

CONCLUSION

This case study illustrates the potential of herbal medicine, particularly Todah Heb-Go, in managing chronic Hepatitis B, especially in patients who do not respond to conventional antiviral treatments. The significant reduction in viral load and the improvement in liver function observed in Quaye's case highlight the need for further exploration of alternative treatment options. Additionally, the study underscores the importance of addressing the social and psychological impacts of Hepatitis B, particularly the stigma associated with the disease.

RECOMMENDATIONS

1. Further Clinical Trials: Conduct larger-scale clinical trials to evaluate the efficacy and safety of Todah Heb-Go in managing chronic Hepatitis B, including its potential role as an adjunctive therapy to conventional antiviral agents.
2. Synergistic Treatment Research: Investigate the possible synergistic effects of combining Todah Heb-Go with existing antiviral therapies like lamivudine and tenofovir to optimize treatment outcomes for patients with chronic Hepatitis B.
3. Patient Education Programs: Develop educational programs to inform patients about the potential benefits and risks of integrating herbal medicine into their treatment plans, ensuring informed decision-making and adherence to therapy.
4. Addressing Social Stigma: Implement community responsiveness crusades and backing groups to address the social humiliation connected with Hepatitis B, concentrating on the psychological well-being of patients and refining their quality of life.

REFERENCES

Chang, T. T., Lai, C. L., Chien, R. N., Guan, R., Lee, C. M., Ng, K. Y., ... & Wilber, R. (2004). Four years of lamivudine treatment in chronic hepatitis B infection: efficacy, safety, and predictive value of early response. Hepatology, 39(1), 135-142

Feng, Y., Tian, T., & Zhang, J. (2016). Clinical efficacy and safety of traditional Chinese medicine for chronic hepatitis B: A systematic review and meta-analysis. PLOS ONE, 11(6), e0157099.

Lee, K. K., Kuo, T. K., & Liu, C. F. (2015). The impact of chronic hepatitis B infection on marriage and pregnancy. Hepatology International, 9(1), 83-92.

Liu, J., Manheimer, E., Tsutani, K., & Gluud, C. (2005). Medicinal herbs for hepatitis B: A Cochrane systematic review of randomized trials. The American Journal of Chinese Medicine, 33(3), 355-367.

Liu, J., Manheimer, E., Yang, M., Wang, D., & Shi, Y. (2003). Herbal medicines for treating chronic hepatitis B infection. Cochrane Database of Systematic Reviews, (4).

Liu, Y., Liu, Z., & Wang, J. (2015). Herbal medicines in the treatment of liver diseases: A focus on the use of herbal medicines for chronic hepatitis B. Evidence-Based Complementary and Alternative Medicine, 2015,

Lok, A. S., & McMahon, B. J. (2009). Chronic hepatitis B. Hepatology, 50(3), 661-662.

Tang, J. L., Liu, B. Y., & Ma, K. W. (2008). Traditional Chinese medicine. The Lancet, 372(9654), 1938-1940.

Wang, B. E. (2000). Treatment of chronic hepatitis B with traditional Chinese medicine. Journal of Gastroenterology and Hepatology, 15(suppl), E67-E70.

Wang, B. S., Chen, H. Z., Yang, Q., & Yuan, W. Q. (2002). Effects of traditional Chinese medicine on chronic hepatitis B. Journal of Traditional Chinese Medicine, 22(4), 321-326.

Wu, X., Zou, H., Liu, T., Liu, X., & Xia, J. (2013). Herbal medicines in the treatment of chronic hepatitis B: An overview. Current Pharmaceutical Design, 19(29), 5445-5453.

Yuen, M. F., Lai, C. L., & Wong, D. K. (2001). Long-term outcome of chronic hepatitis B virus infection treated with lamivudine. Hepatology, 34(4), 767-773.

Zhou, Y., Zeng, L., Zhan, X., Zhang, X., & Zhang, Z. (2015). Traditional Chinese herbal medicines for treating chronic hepatitis B. Journal of Hepatology, 63(4), 948-956.